SCHEMBL365597

SCHEMBL365597

NC(=O)c1cc(F)c(COc2ccc(Cl)c(Cl)c2)cc1F

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 10/20 0.66
SCN5A Q14524 1/20 0.66
PARP10 Q53GL7 6/20 0.50
PARP14 Q460N5 2/20 0.50
PARP15 Q460N3 4/20 0.47
S1PR1 P21453 1/20 0.46
S1PR5 Q9H228 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.43
MAOB P27338 2/20 0.43
MAOA P21397 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16239838 0.88 SCN9A (0.67) SCN9ASCN5AS1PR1S1PR5MRGPRX4
SCHEMBL16239545 0.85 SCN9A (0.70) SCN9ASCN5APARP10PARP14S1PR1
SCHEMBL15543985 0.80 SCN9A (0.65) SCN9ASCN5AS1PR1S1PR5MRGPRX4
SCHEMBL366583 0.80 SCN9A (1.00) SCN9ASCN5A
SCHEMBL15599239 0.79 SCN9A (0.67) SCN9ASCN5APARP10PARP14PARP15
SCHEMBL15018885 0.77 SCN9A (0.88) SCN9ASCN5A
Diethylamine SCHEMBL14890296 0.76 SCN9A (0.90) SCN9ASCN5A
SCHEMBL16239947 0.75 SCN9A (0.74) SCN9ASCN5A
SCHEMBL15018202 0.75 SCN9A (0.89) SCN9ASCN5A
SCHEMBL364456 0.75 SCN9A (0.55) SCN9APARP10PARP15S1PR1S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A SCN9A 16/4885SCN5A 5/4885PARP10 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.